MIGROSTOP COMBINATION PRODUCT CAPSULE

Indications

• Vitiligo
• Hyperpigmentation disorders

Dosage

Children: Refer to BNF for Children for specific dosing guidance.

Adults: Refer to BNF for specific dosing guidance.

Mechanism of action

Monobenzone acts as a depigmenting agent through an incompletely understood mechanism. It is suggested that monobenzone increases the excretion of melanin from melanocytes and interferes with the biosynthesis of melanin by inhibiting the enzyme tyrosinase. This inhibition prevents the conversion of tyrosine to dihydroxyphenylalanine, which is a precursor of melanin. As a result, the drug leads to depigmentation, especially in areas with existing hyperpigmentation, while the epidermis remains intact but lacks identifiable melanocytes.

Pharmacodynamics

Monobenzone is the monobenzyl ether of hydroquinone. It functions as a topical agent that permanently removes color from normal skin surrounding areas affected by vitiligo. By inhibiting the production of melanin, monobenzone reduces skin pigmentation and facilitates a more uniform skin tone over time. The effect is particularly pronounced in hyperpigmented skin, which fades more quickly than normal skin.

Pharmacokinetics

The pharmacokinetics of monobenzone are not extensively detailed in available literature. However, it is primarily applied topically, and its systemic absorption is likely minimal. The onset of action can vary, with effects typically observable within one to four months. The drug is metabolized within the skin, and its efficacy can be influenced by factors such as sun exposure, which can reduce its depigmenting effects.

Adverse effects

• Skin irritation
• Erythema
• Contact dermatitis
• Dry skin
• Photosensitivity

Precautions

• Avoid contact with eyes
• Not for use on broken skin
• Avoid excessive sun exposure

Pregnancy

There are no adequate and well-controlled studies in pregnant women. Use only if clearly needed.

Breast-feeding

There is no information available regarding the excretion of monobenzone in human milk. Caution should be exercised.

Storage

Store at room temperature, away from light and moisture. Keep out of reach of children.

Formulations

• Topical cream
• Topical lotion

Indications

• Herbal medicine for various ailments
• Nutritional supplementation
• Flavoring agents in food
• Support for digestive health
• Management of stress and anxiety

Dosage

Children: Paediatric dosing is dependent on the specific extract and should be determined based on the product guidelines or consulting a healthcare professional familiar with herbal medicine.

Adults: Dosage varies widely based on the specific extract and condition being treated. Refer to product-specific guidelines or consult relevant pharmacological literature for appropriate dosing.

Mechanism of action

The mechanism of action of extracts varies depending on the source material and the specific compounds present. Common mechanisms include modulation of neurotransmitter systems, anti-inflammatory effects, antioxidant activity, and interaction with various cellular pathways. For example, flavonoids in plant extracts may exert antioxidant effects by scavenging free radicals, while alkaloids may influence neurotransmitter receptors.

Pharmacodynamics

The pharmacodynamics of extracts depends on their composition. They may exhibit various effects, such as anti-inflammatory, analgesic, antimicrobial, and immunomodulatory activities. The pharmacological effects are often dose-dependent, with lower doses providing therapeutic benefits and higher doses potentially leading to adverse effects. The time course of action can also vary, with some extracts providing rapid relief and others requiring chronic use to achieve efficacy.

Pharmacokinetics

The pharmacokinetics of extracts depend on the specific compounds and their properties, including solubility, stability, and absorption. Typically, active constituents are absorbed in the gastrointestinal tract and may undergo first-pass metabolism in the liver. The distribution of compounds can vary, affecting their bioavailability and the duration of action. Elimination routes may include renal excretion or metabolic conversion to inactive forms.

Pregnancy

Safety during pregnancy varies depending on the specific extract. Consult specific extract guidelines.

Breast-feeding

Safety during breastfeeding varies depending on the specific extract. Consult specific extract guidelines.

Storage

Store in a cool, dry place away from direct sunlight, and keep out of reach of children.

Indications

• Anti-inflammatory therapy
• Potential cancer treatment
• Traditional medicine applications

Mechanism of action

Parthenium exerts its effects primarily through the inhibition of nuclear factor kappa B (NF-kB) signaling pathways. This action leads to a reduction in the expression of pro-inflammatory cytokines and mediators, thereby demonstrating its anti-inflammatory properties. Additionally, parthenium has shown potential in inducing apoptosis in cancer cells, suggesting a possible role in cancer therapy.

Pharmacodynamics

The pharmacodynamics of parthenium involve modulation of immune responses and inflammatory processes. Its ability to inhibit NF-kB activation results in decreased inflammation and may contribute to its protective effects against certain cancers. The compound's interaction with various cellular pathways suggests a broad spectrum of biological activity, which could be harnessed for therapeutic purposes.

Pharmacokinetics

The pharmacokinetics of parthenium, including its absorption, distribution, metabolism, and excretion (ADME), have not been extensively studied in humans. However, it is anticipated that, like other sesquiterpene lactones, parthenium may exhibit rapid absorption after oral administration, with metabolism occurring predominantly in the liver. The elimination half-life and specific metabolic pathways remain to be fully elucidated.

Indications

• Congestive heart failure
• Cirrhosis
• Renal disease including nephrotic syndrome
• Hypertension
• Acute pulmonary edema

Dosage

Adults: The typical adult dose of furosemide for conditions such as edema is 20-80 mg daily, which may be adjusted based on patient response and clinical condition. For hypertension, doses can range from 40 mg to 120 mg daily.

Mechanism of action

Furosemide promotes diuresis by blocking the tubular reabsorption of sodium and chloride in the proximal and distal tubules and the thick ascending loop of Henle. It achieves this through competitive inhibition of the sodium-potassium-chloride cotransporters (NKCC2), resulting in increased excretion of sodium, chloride, magnesium, calcium, hydrogen, and potassium ions. Additionally, furosemide has vasodilatory effects, reducing responsiveness to vasoconstrictors and enhancing the production of vasodilating prostaglandins.

Pharmacodynamics

Furosemide effectively manages hypertension and edema by increasing the excretion of sodium and water through inhibition of their reabsorption in the nephron. It enhances urine output, with the diuretic effect beginning approximately 1 to 1.5 hours after oral administration, peaking within 2 hours, and lasting 4-6 hours. Intravenous administration leads to a rapid onset of action within 5 minutes, with peak effects at 30 minutes and a duration of approximately 2 hours.

Pharmacokinetics

Furosemide is primarily protein-bound and is secreted via active transport in the kidneys. Following oral administration, its bioavailability is variable, often ranging from 10-90%. The drug undergoes hepatic metabolism to some extent, and its elimination half-life is approximately 1-2 hours. It is excreted largely unchanged in the urine.

Contra-indications

• Hypersensitivity to furosemide or any of its components
• Anuria (failure of the kidneys to produce urine)
• Severe electrolyte depletion

Adverse effects

• Dehydration
• Electrolyte imbalances (e.g., hypokalemia, hyponatremia)
• Hypotension
• Ototoxicity (particularly with rapid intravenous administration)
• Gastrointestinal disturbances (nausea, vomiting)
• Renal impairment

Interactions

• Increased risk of ototoxicity with aminoglycoside antibiotics
• Enhanced hypotensive effect when used with antihypertensives
• Potentially increased nephrotoxicity with NSAIDs
• Reduced efficacy of antidiabetic agents due to hyperglycemia

Precautions

• Monitor renal function and electrolytes regularly
• Use with caution in patients with liver disease
• Caution in patients with diabetes mellitus due to risk of hyperglycemia
• Use cautiously in elderly patients or those with dehydration

Pregnancy

Furosemide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, as it may affect fetal blood flow and hydration.

Breast-feeding

Furosemide is excreted in breast milk; caution should be exercised when administering to nursing mothers.

Storage

Store in a cool, dry place away from direct light. Protect from moisture.

Formulations

• Oral tablets (e.g., 20 mg, 40 mg, 80 mg)
• Oral solution
• Intravenous injection

Indications

• Fever
• Digestive disorders
• Muscle spasms
• Inflammation
• Antimicrobial infections

Dosage

Children: Refer to established herbal medicine guidelines or consult a healthcare professional for appropriate dosing.

Adults: Refer to established herbal medicine guidelines or consult a healthcare professional for appropriate dosing.

Mechanism of action

The primary active constituents of Tanacetum, including thujone and other sesquiterpene lactones, exert their effects through modulation of neurotransmitter systems, particularly affecting GABA receptors. This modulation can lead to muscle relaxation and reduction of spasms. Additionally, its anti-inflammatory properties are attributed to the inhibition of pro-inflammatory cytokines, leading to a reduction in inflammation.

Pharmacodynamics

Tanacetum exhibits a range of pharmacological activities, including anti-inflammatory, antispasmodic, and analgesic effects. Its compounds may also possess antimicrobial properties, aiding in the treatment of infections. The effects are dose-dependent, with lower doses potentially offering therapeutic benefits while higher doses may lead to toxicity. The pharmacodynamic profile suggests a complex interaction with multiple biological pathways, influencing pain perception and inflammation.

Pharmacokinetics

The pharmacokinetics of Tanacetum are not well characterized due to limited research. Generally, the active compounds are absorbed in the gastrointestinal tract and metabolized in the liver. The elimination half-life and specific metabolic pathways remain unclear, and the bioavailability of its components may vary significantly based on preparation and consumption methods. Caution is advised due to potential hepatotoxicity associated with high doses.

Adverse effects

• Allergic reactions
• Gastrointestinal upset
• Headache
• Dizziness

Interactions

• May enhance the effects of anticoagulants
• Possible interaction with antiplatelet drugs
• May interfere with certain antihypertensive medications

Precautions

• Use cautiously in individuals with allergies to plants in the Asteraceae family
• Caution in patients with bleeding disorders
• Monitor for potential gastrointestinal side effects

Pregnancy

Safety during pregnancy has not been established. Use should be avoided unless specifically recommended by a healthcare provider.

Breast-feeding

Safety during breastfeeding is not well-established. Consult a healthcare provider before use.

Storage

Store in a cool, dry place, away from direct sunlight and moisture.

Indications

• Insomnia
• Anxiety disorders
• Stress relief
• Restlessness
• Sleep disturbances

Dosage

Children: Refer to the BNF for Children for specific dosing recommendations for children, as dosing may vary based on age and condition.

Adults: Refer to established dosing guidelines, typically starting with 300-600 mg of valerian extract before bedtime for sleep disorders. Consult specific references for precise dosing recommendations.

Mechanism of action

The precise mechanism of action of valerian is not fully understood. However, it is believed to enhance the action of gamma-aminobutyric acid (GABA), a neurotransmitter that inhibits neural activity, leading to a calming effect on the nervous system. Valerian may increase GABA concentrations in the brain, which helps to promote sleep and reduce anxiety.

Pharmacodynamics

Valerian exhibits sedative and anxiolytic properties, which are primarily attributed to its action on GABA receptors. Its constituents, including valerenic acid and other volatile oils, are thought to interact with the GABAergic system, leading to its calming effects. Additionally, valerian may also have mild muscle relaxant properties and can help alleviate the symptoms of stress and restlessness.

Pharmacokinetics

The pharmacokinetics of valerian are not well characterized due to the complexity of its composition and the variability in its preparation. Valerian is typically administered orally and is absorbed in the gastrointestinal tract. Its onset of action can vary, with effects often noted within 30 minutes to 2 hours after consumption. The half-life of valerian and its active components is not well defined, and they may be subject to metabolic processing in the liver. Excretion is primarily via urine.

Adverse effects

• Drowsiness
• Dizziness
• Gastrointestinal disturbances
• Headache
• Allergic reactions

Interactions

• CNS depressants may enhance sedative effects
• Alcohol may increase drowsiness and sedation
• Benzodiazepines may have additive effects

Precautions

• Use with caution in patients with liver disease
• Not recommended for use in children without medical advice
• Discontinue use before surgery due to sedative effects

Pregnancy

Safety during pregnancy has not been established; use should be avoided unless advised by a healthcare provider.

Breast-feeding

Limited data available; use with caution and consult a healthcare provider.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

• Tablets
• Capsules
• Liquid extracts
• Tea bags

Indications

• Inflammation
• Pain relief
• Antioxidant therapy

Dosage

Children: Refer to specific herbal preparation instructions as doses can vary widely based on the formulation and concentration.

Adults: Refer to specific herbal preparation instructions as doses can vary widely based on the formulation and concentration.

Mechanism of action

The exact mechanism of action of Wallichii is not well-defined. However, it is thought to exert its effects through the modulation of inflammatory pathways and free radical scavenging activity, which can help in reducing oxidative stress and inflammation in the body. These actions may involve the inhibition of pro-inflammatory cytokines and enzymes, although specific molecular pathways are not extensively characterized.

Pharmacodynamics

Wallichii shows pharmacodynamic properties that include anti-inflammatory, antioxidant, and analgesic effects. The active compounds may interact with various cellular pathways to reduce inflammation and pain perception. Additionally, the antioxidant properties may protect cells from oxidative damage, contributing to overall health benefits.

Pharmacokinetics

The pharmacokinetics of Wallichii are not well-studied in the literature. Generally, herbal compounds may be absorbed in the gastrointestinal tract, with metabolism potentially occurring in the liver. The elimination half-life and specific metabolic pathways are not clearly defined, highlighting the need for more research in this area.

Pregnancy

Safety during pregnancy has not been established. Use only if clearly needed and if the potential benefits justify the potential risks to the fetus.

Breast-feeding

It is not known whether wallichii is excreted in human milk. Caution should be exercised when administered to a nursing woman.

Storage

Store in a cool, dry place, away from direct sunlight. Keep out of reach of children.

Mechanism of action

Monobenzone is a depigmenting agent whose mechanism of action is not fully understood. It is proposed that it increases the excretion of melanin from the melanocytes. This effect is erratic and may take one to four months to occur while existing melanin is lost with normal sloughing of the stratum corneum. Hyperpigmented skin appears to fade more rapidly than does normal skin, and exposure to sunlight reduces the depigmenting effect of the drug. Following skin depigmentation after topical application of monobenzone, the histological studies indicate similar results as that seen in vitiligo, where the epidermis is intact but with the absence of identifiable melanocytes. ...INTERFERES WITH BIOSYNTHESIS OF MELANIN. IT INHIBITS ENZYME TYROSINASE & THEREBY PREVENTS CONVERSION OF TYROSINE TO DIHYDROXYPHENYLALANINE, PRECURSOR OF MELANIN.

Pharmacodynamics

Monobenzone is the monobenzyl ether of hydroquinone. Monobenzone, applied topically to the skin, is used as a depigmenting agent inhibitting melanin produced by polymerization of oxidation products of tyrosine and dihydroxyphenyl compounds. Monobenzone works by permanently removing color from normal skin located around skin with vitiligo.

Mechanism of action

Furosemide promotes diuresis by blocking tubular reabsorption of sodium and chloride in the proximal and distal tubules, as well as in the thick ascending loop of Henle. This diuretic effect is achieved through the competitive inhibition of sodium-potassium-chloride cotransporters (NKCC2) expressed along these tubules in the nephron, preventing the transport of sodium ions from the lumenal side into the basolateral side for reabsorption. This inhibition results in increased excretion of water along with sodium, chloride, magnesium, calcium, hydrogen, and potassium ions. As with other loop diuretics, furosemide decreases the excretion of uric acid. Furosemide exerts direct vasodilatory effects, which results in its therapeutic effectiveness in the treatment of acute pulmonary edema. Vasodilation leads to reduced responsiveness to vasoconstrictors, such as angiotensin II and noradrenaline, and decreased production of endogenous natriuretic hormones with vasoconstricting properties. It also leads to increased production of prostaglandins with vasodilating properties. Furosemide may also open potassium channels in resistance arteries. The main mechanism of action of furosemide is independent of its inhibitory effect on carbonic anhydrase and aldosterone. Though both in vivo and in vitro studies have demonstrated an anticonvulsant effect of the loop diuretic furosemide, the precise mechanism behind this effect is still debated. The current study investigates the effect of furosemide on Cs-induced epileptiform activity (Cs-FP) evoked in area CA1 of rat hippocampal slices in the presence of Cs(+) (5mM) and ionotropic glutamatergic and GABAergic receptor antagonists. As this model diverges in several respects from other epilepsy models it can offer new insight into the mechanism behind the anticonvulsive effect of furosemide. The present study shows that furosemide suppresses the Cs-FP in a dose-dependent manner with a near complete block at concentrations = 1.25 mM. Because furosemide targets several types of ion transporters we examined the effect of more selective antagonists. Bumetanide (20 uM), which selectively inhibits the Na-K-2Cl co-transporter (NKCC1), had no significant effect on the Cs-FP. VU0240551 (10 uM), a selective antagonist of the K-Cl co-transporter (KCC2), reduced the ictal-like phase by 51.73 +/- 8.5% without affecting the interictal-like phase of the Cs-FP. DIDS (50 uM), a nonselective antagonist of Cl(-)/HCO3(-)-exchangers, Na(+)-HCO3(-)-cotransporters, chloride channels and KCC2, suppressed the ictal-like phase by 60.8 +/- 8.1% without affecting the interictal-like phase. At 500 uM, DIDS completely suppressed the Cs-FP. Based on these results we propose that the anticonvulsant action of furosemide in the Cs(+)-model is exerted through blockade of the neuronal KCC2 and Na(+)-independent Cl(-)/HCO3(-)-exchanger (AE3) leading to stabilization of the activity-induced intracellular acidification in CA1 pyramidal neurons. Sodium chloride reabsorption in the thick ascending limb of the loop of Henle is mediated by the Na(+)-K(+)-2Cl(-) cotransporter (NKCC2). The loop diuretic furosemide is a potent inhibitor of NKCC2. However, less is known about the mechanism regulating the electrolyte transporter. Considering the well-established effects of nitric oxide on NKCC2 activity, cGMP is likely involved in this regulation. cGMP-dependent protein kinase I (cGKI; PKGI) is a cGMP target protein that phosphorylates different substrates after activation through cGMP. We investigated the potential correlation between the cGMP/cGKI pathway and NKCC2 regulation. We treated wild-type (wt) and cGKIa-rescue mice with furosemide. cGKIa-rescue mice expressed cGKIa only under the control of the smooth muscle-specific transgelin (SM22) promoter in a cGKI deficient background. Furosemide treatment increased the urine excretion of sodium and chloride in cGKIa-rescue mice compared to that in wt mice. We analyzed the phosphorylation of NKC

Pharmacodynamics

Furosemide manages hypertension and edema associated with congestive heart failure, cirrhosis, and renal disease, including the nephrotic syndrome. Furosemide is a potent loop diuretic that works to increase the excretion of Na+ and water by the kidneys by inhibiting their reabsorption from the proximal and distal tubules, as well as the loop of Henle. It works directly acts on the cells of the nephron and indirectly modifies the content of the renal filtrate. Ultimately, furosemide increases the urine output by the kidney. Protein-bound furosemide is delivered to its site of action in the kidneys and secreted via active secretion by nonspecific organic transporters expressed at the luminal site of action. Following oral administration, the onset of the diuretic effect is about 1 and 1.5 hours, and the peak effect is reached within the first 2 hours. The duration of effect following oral administration is about 4-6 hours but may last up to 8 hours. Following intravenous administration, the onset of effect is within 5 minutes, and the peak effect is reached within 30 minutes. The duration of action following intravenous administration is approximately 2 hours. Following intramuscular administration, the onset of action is somewhat delayed.